First-line ibrutinib in untreated CLL: QOL improvement at high cost

    This is a preview of subscription content, log in to check access.

    Reference

    1. Patel KK, et al. Cost-Effectiveness of First-Line Ibrutinib versus Third-Line in Patients with Untreated Chronic Lymphocytic Leukemia. Blood : 9 Jun 2020. Available from: URL: https://doi.org/10.1182/blood.2020004922

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    First-line ibrutinib in untreated CLL: QOL improvement at high cost. PharmacoEcon Outcomes News 856, 16 (2020). https://doi.org/10.1007/s40274-020-6916-0

    Download citation